Vela purchased Great Basin for $1.4 million in June, and will reopen its Utah-based lab, rehire employees, and commercialize the firm's infectious disease platform.
Locus said it will pair the EpiBiome platform with its own CRISPR-based synthetic biology system to develop products that can edit the microbiome.
JPK provides microscopy instrumentation for biomolecular and cellular imaging, as well as force measurements on single molecules, cells, and tissues.
The deal gives Biodesix an additional test in the lung cancer space, Indi's XL2, which helps to classify lung nodules identified by imaging scans as benign or malignant.
Natera led the Index with a 61 percent increase in stock price, driven by the firm's announcement that it was entering the transplantation market.
Through the deal, Precision Therapeutics will acquire the 75 percent stake in Helomics that it does not already own.
Bio-Techne will pay $250 million in cash, as well as up to an additional $325 million contingent on the achievement of certain milestones.
Under a definitive merger agreement, Roche will acquire outstanding shares of Foundation's common stock for $137 per share.
With its purchase of decision support technology maker Interactive Biosoftware, Sophia looks to extend its AI platform deeper into NGS interpretation.
The merger, which was previously scuttled and later revived with Rosetta shareholder approval, was due to close on May 27.
Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.
St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.
St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.
In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.